{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Advanced&page=5", "query": { "condition": "Cancer, Advanced", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 9813, "total_pages": 982, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Advanced&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Advanced&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T09:56:27.932Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04387084", "title": "Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Skin Neoplasm", "Metastatic Malignant Skin Neoplasm" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Short-Term Fasting", "type": "OTHER" }, { "name": "Dostarlimab", "type": "BIOLOGICAL" }, { "name": "Retifanlimab", "type": "BIOLOGICAL" }, { "name": "Toripalimab", "type": "BIOLOGICAL" }, { "name": "Tislelizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2020-08-12", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-11-05T09:56:27.932Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04387084" }, { "nct_id": "NCT00001338", "title": "A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Fever", "Hematologic Diseases", "Neutropenia", "Sepsis" ], "interventions": [ { "name": "FLAC chemotherapy with GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 65, "start_date": "1993-06", "completion_date": "2001-01", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-11-05T09:56:27.932Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001338" }, { "nct_id": "NCT06328738", "title": "ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER2 Positive Solid Tumors", "HER2 Amplification", "Colorectal Cancer" ], "interventions": [ { "name": "ELVN-002", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Enliven Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2024-05-30", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-11-05T09:56:27.932Z", "location_count": 3, "location_summary": "Plantation, Florida • St Louis, Missouri • Fairfax, Virginia", "locations": [ { "city": "Plantation", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06328738" }, { "nct_id": "NCT07548476", "title": "Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Bladder Cancer", "Peripheral Neuropathy", "Advanced Urothelial Cancer", "Metastatic Urothelial Cancer", "Bladder Cancer", "Urothelial Cancer" ], "interventions": [ { "name": "Acupuncture", "type": "PROCEDURE" }, { "name": "Exercise", "type": "BEHAVIORAL" } ], "intervention_types": [ "PROCEDURE", "BEHAVIORAL" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-09-03", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-05T09:56:27.932Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07548476" }, { "nct_id": "NCT01924689", "title": "Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor Malignancies" ], "interventions": [ { "name": "Clostridium novyi-NT spores", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BioMed Valley Discoveries, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2013-10", "completion_date": "2017-10-31", "has_results": true, "last_update_posted_date": "2019-09-09", "last_synced_at": "2026-11-05T09:56:27.932Z", "location_count": 5, "location_summary": "St Louis, Missouri • New York, New York • The Bronx, New York + 2 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01924689" }, { "nct_id": "NCT01142401", "title": "Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Carcinoma", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 118, "start_date": "2010-05-26", "completion_date": "2021-01-08", "has_results": true, "last_update_posted_date": "2023-11-27", "last_synced_at": "2026-11-05T09:56:27.932Z", "location_count": 21, "location_summary": "Farmington, Connecticut • New Haven, Connecticut • Weston, Florida + 8 more", "locations": [ { "city": "Farmington", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Weston", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01142401" }, { "nct_id": "NCT00559507", "title": "Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-negative Breast Cancer", "Male Breast Cancer", "Progesterone Receptor-negative Breast Cancer", "Recurrent Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "saracatinib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2007-10", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2014-04-30", "last_synced_at": "2026-11-05T09:56:27.932Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00559507" }, { "nct_id": "NCT00729664", "title": "Multiple Ascending Dose (MDX1105-01)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer, Multiple Indications" ], "interventions": [ { "name": "Anti-PDL-1 antibody", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 281, "start_date": "2009-02", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2015-09-07", "last_synced_at": "2026-11-05T09:56:27.932Z", "location_count": 11, "location_summary": "Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00729664" }, { "nct_id": "NCT01393509", "title": "The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumor", "Lymphoma", "Myeloproliferative Neoplasms (MPN)" ], "interventions": [ { "name": "PU-H71", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2011-07-06", "completion_date": "2023-03-23", "has_results": false, "last_update_posted_date": "2023-03-28", "last_synced_at": "2026-11-05T09:56:27.932Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01393509" }, { "nct_id": "NCT00991952", "title": "Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "Diffuse Adenocarcinoma of the Stomach", "Intestinal Adenocarcinoma of the Stomach", "Mixed Adenocarcinoma of the Stomach", "Recurrent Gastric Cancer", "Stage IIIA Gastric Cancer", "Stage IIIB Gastric Cancer", "Stage IIIC Gastric Cancer", "Stage IV Gastric Cancer" ], "interventions": [ { "name": "alvocidib", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2009-09", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2014-05-26", "last_synced_at": "2026-11-05T09:56:27.932Z", "location_count": 5, "location_summary": "Duarte, California • Sacramento, California • Chicago, Illinois + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00991952" } ] }